MacroGenics, Inc.
MGNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, MacroGenics, Inc. (MGNX) is listed under Biotechnology. The $262.5M market capitalization puts MGNX squarely in micro-cap range for its industry. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Market Cap
$262.5M
Beta
1.20
P/E (TTM)
—
P/E (Fwd)
-2.92
EPS (TTM)
$-1.11
EPS (Fwd)
$-1.41
ROE
-140.3%
ROA
-18.0%
Cash
$154.2M
Total Debt
$36.5M
Free CF
$10.1M
52W Change
215.3%
Annual Financials
Cash vs Debt
With $154.2M in cash and $36.5M in debt, MGNX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $10.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -140.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $150.0M (2022) to $149.5M (2025).
With cash comfortably exceeding debt, MGNX has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MGNX.